Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery....

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

BioTechHealthX Mar. 8 at 6:53 PM

$CORT Corcept Therapeutics (NASDAQ: CORT) is gaining major attention after analysts highlighted a potential 174% upside fueled by its cancer and endocrine drug pipeline. With an approved therapy already generating revenue and the promising relacorilant program advancing in clinical trials, CORT stock is emerging as a compelling biotech growth story. https://biotechhealthx.com/biotech-news/should-you-now-start-buying-corcept-therapeutics-cort-shares/

0 · Reply

BioTechHealthX Mar. 8 at 4:33 PM

$BEAM $CORT $DYN $LEGN $OLMA Looking for the best biotechnology stocks to buy now? Analysts say these 10 biotech stocks could deliver more than 50% upside as breakthroughs in gene therapy, immuno-oncology, and RNA medicine reshape the healthcare industry. https://biotechhealthx.com/biotech-news/10-best-biotechnology-stocks-to-buy-now-with-more-than-50-upside-potential/

1 · Reply

gucag006 Mar. 7 at 9:22 AM

$CORT Understand the dynamics of authorized generic (AG) vs. generic. During Q4/25 ER call, CORT's management mentioned that they have been transitioning their Cushing syndrome customers from branded Korlym to AG. By EOY/25 75% has been converted, and they expect it will settle at 78% by EOY/26. For rare disease drug, according to Gemini AI, the impact on the price is minimum, while the battle ground is the rebates offered to PBBM's and Medicare Part D plans:

1 · Reply

UnoffensiveName Mar. 5 at 8:51 PM

$CORT CONSTANTLY mentioning it

0 · Reply

UnoffensiveName Mar. 5 at 8:49 PM

$CORT how many times are they going to mention the lawsuit in the news feed.

0 · Reply

druvaciam Mar. 5 at 5:11 PM

$CORT Extremely weak, no buyers.

1 · Reply

ZacksResearch Mar. 5 at 4:34 PM

$CORT revenue climbing… but a legal cloud is forming. ⚖️📈 Korlym sales jumped 13% Y/Y in 2025, fueling Corcept’s growth, and 2026 revenues are seen at $900M–$1B — a strong trajectory if momentum holds. But a court ruling favoring Teva’s generic could put pressure on future Korlym sales, creating a key risk investors can’t ignore. Full risk/reward picture here 👉 https://www.zacks.com/stock/news/2879144/corcepts-korlym-drives-its-2025-revenue-surge-whats-ahead?cid=sm-stocktwits-2-2879144-teaser-36119&ADID=SYND_STOCKTWITS_TWEET_2_2879144_TEASER_36119

0 · Reply

ZacksResearch Mar. 5 at 3:34 PM

$CORT faces a rough road ahead — is the stock in trouble? ⚠️ 📉 Shares down 49.9% YTD, significantly underperforming the industry 📊 Zacks Consensus Estimate for 2026 EPS slashed from 84 cents to 29 cents 💊 Federal court ruling opens the door for a generic Korlym, threatening future sales Understand the risks before investing in CORT 👉 https://www.zacks.com/stock/news/2879144/corcepts-korlym-drives-its-2025-revenue-surge-whats-ahead?cid=sm-stocktwits-2-2879144-body-36118&ADID=SYND_STOCKTWITS_TWEET_2_2879144_BODY_36118

0 · Reply

BillionerOfKing Mar. 4 at 4:02 AM

$CORT Current Stock Price: $35.26 Contracts to trade: $35.0 CORT Mar 20 2026 Call Entry: $1.45 Exit: $2.31 ROI: 59% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Daniech0514 Mar. 3 at 5:19 AM

$CORT article on ovarian cancer trial. Of note liver function test abnormalities were LOWER in the relicorilant +Nab arm vs Nab alone 5% vs 9% https://www.cancernetwork.com/view/relacorilant-plus-nab-paclitaxel-significantly-improves-survival-in-proc?ekey=RUtJRDowQTU2QUQ5RS0zNUVCLTQ1REYtQjlCNi0zRDM4NDhCQTAxRDQ%3D&utm_campaign=emailname&utm_medium=email&_hsenc=p2ANqtz-9FvBxyOFqZKV4zwsmi_95cNjrh5dVgbH1j4yvXN8U0p1gso5hZBmQMoGoRPsAcJgrwCNuQBmdTDILi71sT4C314bnPUA&_hsmi=406483884&utm_source=hs

0 · Reply

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT

Feb 24, 2026, 7:47 PM EST - 12 days ago

Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:05 PM EST - 12 days ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Feb 20, 2026, 7:30 AM EST - 17 days ago

Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not

Feb 19, 2026, 4:00 PM EST - 17 days ago

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Feb 19, 2026, 11:48 AM EST - 17 days ago

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Feb 17, 2026, 4:05 PM EST - 19 days ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Feb 9, 2026, 10:58 AM EST - 27 days ago

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Feb 9, 2026, 4:54 AM EST - 4 weeks ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Feb 4, 2026, 2:24 PM EST - 4 weeks ago

Allspring Emerging Growth Fund Q4 2025 Performance Review

AMSC ATI CRS CSTL CVLT CWAN TARS

Feb 4, 2026, 8:42 AM EST - 4 weeks ago

Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman

Jan 30, 2026, 8:32 PM EST - 5 weeks ago

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

Jan 30, 2026, 2:20 PM EST - 5 weeks ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 10:36 AM EST - 5 weeks ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 30, 2026, 10:13 AM EST - 5 weeks ago

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses

Jan 22, 2026, 11:12 AM EST - 6 weeks ago

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Jan 22, 2026, 8:13 AM EST - 6 weeks ago

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:00 AM EST - 6 weeks ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 15, 2026, 10:31 AM EST - 7 weeks ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Jan 14, 2026, 9:52 PM EST - 7 weeks ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Jan 14, 2026, 11:56 AM EST - 7 weeks ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

Jan 13, 2026, 9:43 AM EST - 7 weeks ago

CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Jan 12, 2026, 12:11 PM EST - 7 weeks ago

Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 9, 2026, 3:24 PM EST - 2 months ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman

Jan 9, 2026, 10:00 AM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

Jan 7, 2026, 2:33 PM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 4, 2026, 7:08 AM EST - 2 months ago

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug

Dec 31, 2025, 4:02 PM EST - 2 months ago

Why Corcept Therapeutics stock crashed today and what comes next?

Dec 31, 2025, 12:31 PM EST - 2 months ago

Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug

Dec 31, 2025, 8:05 AM EST - 2 months ago

US FDA declines to approve Corcept's drug for rare hormonal disorder

Dec 31, 2025, 8:00 AM EST - 2 months ago

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

Dec 22, 2025, 11:41 AM EST - 2 months ago

Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

BioTechHealthX Mar. 8 at 6:53 PM

0 · Reply

BioTechHealthX Mar. 8 at 4:33 PM

1 · Reply

gucag006 Mar. 7 at 9:22 AM

1 · Reply

UnoffensiveName Mar. 5 at 8:51 PM

$CORT CONSTANTLY mentioning it

0 · Reply

UnoffensiveName Mar. 5 at 8:49 PM

$CORT how many times are they going to mention the lawsuit in the news feed.

0 · Reply

druvaciam Mar. 5 at 5:11 PM

$CORT Extremely weak, no buyers.

1 · Reply

ZacksResearch Mar. 5 at 4:34 PM

0 · Reply

ZacksResearch Mar. 5 at 3:34 PM

0 · Reply

BillionerOfKing Mar. 4 at 4:02 AM

0 · Reply

Daniech0514 Mar. 3 at 5:19 AM

0 · Reply

SuperGreenToday Mar. 2 at 9:01 PM

$CORT Share Price: $35.96 Contract Selected: Aug 21, 2026 $35 Calls Buy Zone: $6.97 – $8.61 Target Zone: $11.36 – $13.89 Potential Upside: 54% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

biotech Feb. 27 at 3:34 PM

$XERS filed a patent infringement #lawsuit vs Torrent and Somerset each of which filed ANDA") with the FDA seeking approval to manufacture, use or sell a #generic version of #Recorlev Xeris's complaint seeks an injunction to prevent the manufacture, use, and sale of generic R. re $TEVA $CORT

0 · Reply

DixonCider Feb. 27 at 1:23 PM

$XERS Two companies jumped on the first opportunity to file for generic. They know all well this is going to be dismissed but they could get 1st generic exclusivity for 180 days YEARS from now. This shows how big the market is but also just the normal Indian garbage company trying to snake away 🇺🇸 made and patent products without doing any actual work. Suck my balls Also between $CORT & $XERS we will do probably $1.3-1.4B in revenue on Cushing while our stock market cap sits at $1.1B all in right now 🧐 (Gvoke, Levo, Keyvsis, technology not worth anything I guess) 🫡 John you better fuckin delivery Monday

3 · Reply

gucag006 Feb. 26 at 10:55 PM

$CORT Now we heard from the management first hand: - There are daylights between FDA's analysis of Relacorilant's efficacy and theirs - new method of analysis never heard of by FDA, - Relacorilant's safety profile is consistent and sound, need to hear from FDA on the supering liver-enzyme concern, - Authorized generic (AG) program has long been put in place since last year. 75% of the prescriptions are under AG already, and projected to settle at 78% by the end of 2026. Despite the generics, their problem was not demand, but supplies - they couldn't manufacture Korlym fast enough to meet the demand. Now the supply bottleneck is completely behind them now. Let's sit tight and wait until they talk to FDA in April. Don't forget 7/11/26 PROC relief date. In the meantime, the SP will climb back to $80S this year, and hit $150 next year. Cheers!

1 · Reply

UnoffensiveName Feb. 26 at 2:02 PM

$CORT Man... The TOs News feed sure does like to repeatedly remind us of the class action lawsuit. Must have repeated it on the feed a dozen times. Bias much?

0 · Reply

OX50 Feb. 25 at 5:42 PM

$CORT Latest Report 02/24/2026 LSEG maintains a current price target of $84 for CORT

0 · Reply

Apes_Strong Feb. 25 at 5:23 PM

$CORT of wainright is at a 12 month target of 60 that’s a downgrade

1 · Reply

druvaciam Feb. 25 at 5:13 PM

$CORT Analysts downgrades are coming most likely.

0 · Reply

Apes_Strong Feb. 25 at 5:09 PM

$CORT stop being sheep

0 · Reply

Apes_Strong Feb. 25 at 5:08 PM

$CORT here’s what you can expect revenue this year This Q $240 mil Next $210 Next $180 Next $160 Total 790 Next year 550-600 (without oncology) If CRL lifted and Cushing’s approved then that would add incremental Stock will see $25 before any of this comes to light

1 · Reply

ZacksResearch Feb. 25 at 3:38 PM

$CORT just stumbled — growth wasn’t enough this time. ⚠️ Q4 earnings and revenues both missed estimates, even with sales up 11% year over year. That kind of top-line growth should translate better… but it didn’t. Is this a short-term hiccup or a deeper margin issue? Get the full breakdown 👉 https://www.zacks.com/stock/news/2874938/corcepts-q4-earnings-and-revenues-fall-short-of-estimates?cid=sm-stocktwits-2-2874938-teaser-35068&ADID=SYND_STOCKTWITS_TWEET_2_2874938_TEASER_35068

0 · Reply

Apes_Strong Feb. 25 at 2:53 PM

$CORT you’re not listening They are never going to hit those numbers

2 · Reply

Market Cap	3.60B
Revenue (ttm)	761.41M
Net Income (ttm)	99.65M
EPS (ttm)	N/A
PE Ratio	41.51
Forward PE	116.38
Profit Margin	13.09%
Debt to Equity Ratio	0.00

Volume	1,230,000
Avg Vol	2,467,264
Day's Range	N/A - N/A
Shares Out	106.37M
Stochastic %K	17%
Beta	0.29
Analysts	Sell
Price Target	$65.40